ABOS (STOCKS)
Acumen Pharmaceuticals, Inc. Common Stock
$2.260000
+0.010000 (+0.44%)
Prev close: $2.250000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Daniel J. O'Connell
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $163.23M
- Employees
- 52
- P/E (TTM)
- -1.22
- P/B (TTM)
- 1.87
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.33 | $-0.41 | +0.0808 | +19.67% |
|
Dec 2025 (Q4)
|
$-0.41 | $-0.46 | +0.0522 | +11.29% |
|
Sep 2025 (Q3)
|
$-0.44 | $-0.62 | +0.1757 | +28.54% |
|
Jun 2025 (Q2)
|
$-0.68 | $-0.55 | -0.1312 | -23.91% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $1.34M |
| Operating Expenses | $114.61M |
| Research and Development | $96.10M |
| Other Operating Expenses | $18.51M |
| Operating Income/Loss | -$114.61M |
| Income/Loss From Continuing Operations After Tax | -$113.28M |
| Income/Loss From Continuing Operations Before Tax | -$113.28M |
| Net Income/Loss | -$113.28M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$113.28M |
| Net Income/Loss Available To Common Stockholders, Basic | -$113.28M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.86 |
| Diluted Earnings Per Share | -$1.86 |
| Basic Average Shares | 184,370,307 |
| Diluted Average Shares | 184,370,307 |
| Assets | $133.63M |
| Current Assets | $133.09M |
| Noncurrent Assets | $535.00K |
| Fixed Assets | $91.00K |
| Other Non-current Assets | $444.00K |
| Liabilities | $46.15M |
| Current Liabilities | $29.23M |
| Accounts Payable | $1.66M |
| Other Current Liabilities | $27.57M |
| Noncurrent Liabilities | $16.92M |
| Long-term Debt | $16.92M |
| Equity | $87.48M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $87.48M |
| Liabilities And Equity | $133.63M |
| Net Cash Flow From Operating Activities | -$105.55M |
| Net Cash Flow From Operating Activities, Continuing | -$105.55M |
| Net Cash Flow From Investing Activities | $91.44M |
| Net Cash Flow From Investing Activities, Continuing | $91.44M |
| Net Cash Flow From Financing Activities | $35.74M |
| Net Cash Flow From Financing Activities, Continuing | $35.74M |
| Net Cash Flow | $21.64M |
| Net Cash Flow, Continuing | $21.64M |
| Comprehensive Income/Loss | -$113.27M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$113.27M |
| Other Comprehensive Income/Loss | -$113.27M |